新型生物标志物在急性肾损伤诊断、预后及管理中的应用：急性透析质量倡议（ADQI）第十次共识会议执行摘要
Implementation of novel biomarkers in the diagnosis, prognosis, and management of acute kidney injury: executive summary from the tenth consensus conference of the Acute Dialysis Quality Initiative (ADQI).
作者信息
McCullough Peter A, Bouchard Josee, Waikar Sushrut S, Siew Edward D, Endre Zoltan H, Goldstein Stuart L, Koyner Jay L, Macedo Etienne, Doi Kent, Di Somma Salvatore, Lewington Andrew, Thadhani Ravi, Chakravarthi Raj, Ice Can, Okusa Mark D, Duranteau Jacques, Doran Peter, Yang Li, Jaber Bertrand L, Meehan Shane, Kellum John A, Haase Michael, Murray Patrick T, Cruz Dinna, Maisel Alan, Bagshaw Sean M, Chawla Lakhmir S, Mehta Ravindra L, Shaw Andrew D, Ronco Claudio
机构信息
St. John Providence Health System, Warren, MI, USA.
出版信息
Contrib Nephrol. 2013;182:5-12. doi: 10.1159/000349962. Epub 2013 May 13.
Detection of acute kidney injury is undergoing a dynamic revolution of biomarker technology allowing greater, earlier, and more accurate determination of diagnosis, prognosis, and with powerful implication for management. Biomarkers can be broadly considered as any measurable biologic entity or process that allows differentiation between normal function and injury or disease. The ADQI (Acute Dialysis Quality Initiative) had its Ninth Consensus Conference dedicated to synthesis and formulation of the existing literature on biomarkers for the detection of acute kidney injury in a variety of settings. In the papers that accompany this summary, ADQI workgroups fully develop key concepts from a summary of the literature in the domains of early diagnosis, differential diagnosis, prognosis and management, and concurrent physiologic and imaging measures.
急性肾损伤的检测正经历生物标志物技术的动态变革，这使得对诊断、预后的判定更加全面、更早且更准确，对治疗也具有重大意义。生物标志物可广义地定义为任何可测量的生物实体或过程，它能够区分正常功能与损伤或疾病状态。急性透析质量倡议组织（ADQI）的第九次共识会议致力于综合和阐述现有文献中关于在各种情况下检测急性肾损伤的生物标志物。在本综述所附的论文中，ADQI工作组从早期诊断、鉴别诊断、预后和治疗以及同时进行的生理和影像学测量等领域的文献综述中全面深入地探讨了关键概念。
Zotero 插件